Up 2,000% in a year, why this ASX healthcare stock is in focus today

4DMedical Ltd (ASX: 4DX) is back on the radar after an active start to the week.

The stock is currently up 2.56% to $5.99 after earlier touching an intraday high of $6.38.

That pullback has come as the broader market softened, with the S&P/ASX 200 Index (ASX: XJO) down 0.1% to 8,935 points.

Even with today’s volatility, the overall trend remains strong. The shares are up roughly 50% in 2026 and 2,000% over the past year.

Here’s what was announced.

Several updates hit at the same time

According to the release, 4DMedical reported a series of developments across commercial, regulatory, and its upcoming inclusion in the ASX 200.

The company confirmed a contract with GlaxoSmithKline to support pulmonary drug development using its imaging technology.

GlaxoSmithKline is a global pharmaceutical and healthcare company headquartered in the UK. It develops vaccines, specialty medicines, and consumer health products, and is one of the largest drugmakers in the world.

The agreement runs for 1 year and will see 4DMedical provide lung imaging biomarkers across clinical trials.

4DMedical did not disclose the financial terms of the agreement.

At the same time, the company reported regulatory clearance in the UK for its CT:VQ technology.

CT:VQ is 4DMedical’s imaging technology that uses CT scans to map how air and blood move through the lungs. It produces detailed functional images that help clinicians detect and measure lung conditions without requiring invasive tests.

This follows CE Mark certification received in March and allows for immediate clinical use.

The UK is one of the largest markets for diagnostic imaging, with millions of chest scans performed each year.

The update also highlighted clearance for its coronary artery calcium analysis solution in Canada.

Reimbursement progress opens a revenue pathway

Another part of the release focused on progress in the United States.

A new reimbursement code has been established for AI-enabled coronary calcium analysis from CT scans.

The code allows hospitals to claim around US$15.50 per study in the outpatient setting.

This puts a clear revenue pathway in place without requiring additional imaging or changes to workflow. Providers can integrate the analysis into existing scans, which helps lower barriers to adoption.

Reimbursement has often been a key step in moving imaging technologies into routine clinical use.

ASX 200 entry puts the stock on more screens

4DMedical has also been added to the S&P/ASX 200 Index at market open today.

The move brings the stock into Australia’s main benchmark, which is tracked by institutional and passive funds.

Inclusion can lead to increased demand as index funds adjust their holdings.

It also increases visibility among larger investors and can improve liquidity over time.

The post Up 2,000% in a year, why this ASX healthcare stock is in focus today appeared first on The Motley Fool Australia.

More reading

• Worley flags $30–40m EBITA hit from Middle East conflict in FY26 outlook
• Viva Energy Group issues update on Geelong Refinery after fire
• Qube updates FY26 outlook: expects short-term headwinds but maintains earnings growth target
• National Australia Bank strengthens balance sheet ahead of 1H26 results
• NextDC reports 60% increase in contracted utilisation growth and higher capex guidance

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.